media – Page 123 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Yingen Biotech starts IPO today and is expected to be listed on April 15

Yingen Biotech plans to be officially listed on the Hong Kong Stock Exchange on April 15, and has received support from a lineup of luxurious cornerstone investors including BioNTech. Yingen Biotech was founded in 2019 and focuses on the research and development of antibody-drug conjugates (ADCs) to treat cancer and autoimmune diseases. The company has two core products: DB-1303/BNT323 is an ADC candidate targeting HER2 for the treatment of endometrial cancer and breast cancer. DB-1311/BNT324 is an ADC candidate targeting B7-H3 for the treatment of small cell lung cancer, castration-resistant prostate cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. In addition to its core products, Yingen Bio also has five other ADC drugs in clinical stage, namely DB-1310, DB-1305/BNT325, DB-1312/BGC9074, DB-1419 and DB-2304, with a wide range of indications; two bispecific ADCs (BsADCs): DB-1418/AVZO-1418 and DB-1421, which are expected to enter the clinical stage from 2025 ...
- Source: drugdu
- 457
- April 8, 2025
China’s biomanufacturing begins to use rice to make blood

“Rice makes blood”, a concept that sounds “fairy tale”, has now become a reality in a biopharmaceutical company in Wuhan. Human serum albumin manufactured in this way is not only safer and more environmentally friendly, but also has the advantages of large-scale production and low cost. It is expected to become an important solution to alleviate the shortage of human serum albumin in my country. At present, the human serum albumin product developed using this technology has completed phase III clinical trials and entered the new drug approval process. The team has built an intelligent factory with an annual output of 1 million injections and is building a large-scale production base with an annual output of 12 million injections. https://finance.eastmoney.com/a/202504063365597167.html
- Source: drugdu
- 231
- April 8, 2025
Firmly oppose! China Chamber of Commerce for Import and Export of Medicines and Health Products issued a statement on the so-called “reciprocal tariffs” imposed by the United States

On April 5, China Chamber of Commerce for Import and Export of Medicines and Health Products issued a statement on the so-called “reciprocal tariffs” imposed by the United States. On April 2, 2025, Eastern Time, the US government announced the imposition of so-called “reciprocal tariffs” on all trading partners, including China. Most medical consumables, dressings, medical equipment and its parts, rehabilitation supplies and other products are affected, especially some products are superimposed on the unreasonable tax increase measures of the US government in the past, and the tariffs have reached extremely high levels. The unilateral trade measures of the US government ignore the rules of the World Trade Organization, which will not only seriously affect the production and operation of global pharmaceutical industry companies including China, but also seriously affect the research and development, production and stability of the global pharmaceutical industry supply chain, and damage the health and well-being ...
- Source: drugdu
- 215
- April 8, 2025
CMEF Guangzhou

Organiser: Reed Sinopharm Exhibitions Time: September 26 – 29, 2025 Address: No. 380, Yuejiang Middle Road, Haizhu District, Guangzhou City Exhibition hall: Canton Fair Complex – Pazhou Hall, Guangzhou Product range: Medical Imaging Zone: Radiology products, ultrasound products, nuclear medicine products, molecular imaging, interventional products, etc. Operating Room Zone: Hybrid operating rooms, integrated operating room solutions, surgical instruments, anesthesia machines, ventilators, patient monitors, operating room engineering, surgical lights, pendant systems, etc. In Vitro Diagnostics Zone: Total laboratory solutions, clinical diagnostic equipment, diagnostic reagents, POCT (Point-of-Care Testing), home diagnostic devices, etc. Rehabilitation & Physiotherapy Zone: Rehabilitation equipment, assistive devices, traditional Chinese medicine treatments, physiotherapy equipment, medical high-frequency devices, etc. Orthopedics Zone: Orthopedic implants (joints, trauma, spine), orthopedic surgical instruments and equipment, bone power tools, and other orthopedic-related products. Medical Informatics Zone: System integrators, mobile healthcare, medical management, quality control, clinical hospital information management systems, IT equipment providers (display, printing, storage), ...
- Source: drugdu
- 286
- April 8, 2025
Orthopedic giant Stryker announced the completion of the sale of this business

According to foreign media reports, on April 1, global orthopedic giant Stryker announced that it had completed the sale of its US spinal implant business to Viscogliosi Brothers, LLC, a family investment company focusing on the neuromusculoskeletal field. It is worth noting that the transaction led to the establishment of a new company called VB Spine, LLC (VB Spine), which also marked the official implementation of Stryker’s business restructuring plan announced in January this year. Previously, Stryker stated that in addition to the US market, its international spinal implant business will also be gradually divested. From Stryker’s 2024 financial report, it can be seen that its spinal implant business can no longer help the company’s revenue. The financial report shows that in 2024, its spinal implant business revenue was US$707 million (a year-on-year decrease of 0.7%), of which the US spinal implant business decreased by 2.1% year-on-year. The specific financial ...
- Source: drugdu
- 172
- April 7, 2025
Yangtze River Pharmaceuticals enters the race for Elamod

Recently, the official website of the National Medical Products Administration (NMPA) showed that Yangtze River Pharmaceutical’s Aguratimod tablets, which were applied for as a generic 4 drug, were officially approved for marketing, becoming the second company in China to have its generic drug approved and pass the consistency evaluation. This progress not only marks a further breakthrough for Yangtze River Pharmaceutical in the field of anti-rheumatic diseases, but also provides more treatment options for domestic patients with rheumatoid arthritis. Eguratimod tablets are a new type of disease-modifying antirheumatic drug (DMARDs) that has both anti-inflammatory and immunomodulatory mechanisms. It can inhibit the production of inflammatory factors such as IL-6 and TNF-α, while delaying bone erosion and promoting bone formation. Clinical data show that it can be effective in 2-4 weeks when used in combination with methotrexate, with a patient remission rate of over 60%, and significantly lower liver toxicity and infection ...
- Source: drugdu
- 312
- April 7, 2025
Huadong Medicine, a leader in diabetes, has its domestic application for semaglutide accepted

On the evening of April 1, 2025, Huadong Medicine Co., Ltd. (stock code: 000963.SZ, hereinafter referred to as “Huadong Medicine”) issued an announcement stating that the company’s wholly-owned subsidiary Hangzhou Sino-US Huadong Pharmaceutical Jiangdong Co., Ltd. (hereinafter referred to as “Jiangdong Company”) received the “Acceptance Notice” issued by the National Medical Products Administration (NMPA), and the application for marketing authorization of semaglutide injection was accepted. The indication for this application is blood sugar control in adult patients with type 2 diabetes. In addition, the clinical trial application for the fluid re-management indication of semaglutide injection was approved by NMPA in September 2024, and the first subject was enrolled in the Phase III clinical trial in December 2024. Due to the excellent and popular hypoglycemic and weight loss effects of semaglutide, its biosimilars will face huge market opportunities when they are launched. Semaglutide becomes the “King of GLP-1 Drugs” and has ...
- Source: drugdu
- 871
- April 7, 2025
Another mRNA company emerges

Despite fierce market competition, SiliDi Pharmaceuticals delivered a “cost reduction and efficiency improvement” report card in 2024: revenue declined but losses narrowed significantly, sales of its core product Envida grew by 15.9% in the second half of the year against the trend, and the mRNA tumor vaccine pipeline achieved key breakthroughs. How will this innovative pharmaceutical company make a comeback in the future? Sales of core products declined According to the financial report, in 2024, SiliDi achieved revenue of approximately RMB 446 million, a year-on-year decrease of 29.8%; gross profit was RMB 409 million, a year-on-year decrease of 30.2%. In addition, thanks to a significant reduction in R&D expenses and sales and marketing expenses (down 57.5% and 37.7% respectively), the full-year net loss narrowed to RMB 199 million, a year-on-year decrease of 64.6%. Subcutaneous injection of PD-L1 Envolimab (trade name: Envida) is the only commercialized product of SilDi, and the ...
- Source: drugdu
- 232
- April 7, 2025
the first round of measures targets more than $28 billion in goods

As US President Trump’s tariff hurricane hits global markets and economic prospects, EU countries will seek to form a united front in the coming days to determine the first round of countermeasures against US tariffs. According to media reports, the EU may approve tariffs on US imports worth up to $28 billion on Wednesday, which will be the EU’s first round of targeted retaliatory tariffs against the United States. This move will mean that the EU will join China and Canada in fighting back against the United States. The EU will fight back against the United States Automobiles, steel and aluminum products from the 27 EU countries are already facing a 25% import tariff from the United States. And starting from Wednesday this week, almost all other goods from the EU will also face a so-called “reciprocal tariff” of 20%. Trump’s tariffs now cover about 70% of EU exports to ...
- Source: drugdu
- 193
- April 7, 2025
Liraglutide obtains FDA approval, and global layout leads Chinese pharmaceutical companies to go overseas

On April 3, Jianyou Shares (603707) issued an announcement that the company recently received an approval letter for liraglutide injection, 18 mg/3 mL (6 mg/mL), (ANDA No.: 218115) issued by the US Food and Drug Administration. The drug has a specification of 18mg/3mL (6mg/mL) and can be used as an adjunct to diet and exercise to improve blood sugar control in adults and children aged 10 years and above with type 2 diabetes, while reducing the risk of major adverse cardiovascular events in adult patients with type 2 diabetes with cardiovascular disease. So far, the company has invested approximately RMB 57.37 million in the research and development project of liraglutide injection. The newly approved product will be available in the United States in the near future and is expected to have a positive impact on the company’s operating performance. This event has become an important window for observing its global ...
- Source: drugdu
- 307
- April 7, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.